Adrian Adams to helm Neurologix; Bird flu expert warns against ignoring new outbreaks;

 @FierceBiotech: JDRF presents a $100,000 challenge for breakthrough ideas on diabetes. Item | Follow @FierceBiotech

 @JohnCFierce: Tokai (Cambridge, MA) lands new CEO, $23M venture round for PhIIb cancer study. Report | Follow @JohnCFierce

 @RyanMFierce: I hope to see lots of Boston biotechies at Oct. 19 breakfast featuring R&D heads at Biogen, Vertex and @JohnCFierce. Info | Follow @RyanMFierce

@MaureenFierce: Giving flu vaccine to kids 2 to 4 cuts ER visits for flu-like symptoms by a third. Story | Follow @MaureenFierce

 @FierceMedDev: Varian Medical Systems inks deal to buy Calypso Medical Technologies. Release | Follow @FierceMedDev

> Adrian Adams, the former CEO of Inspire, has been named CEO of the gene therapy company Neurologix. In addition, Andrew I. Koven joins the Neurologix executive team as president and chief administrative officer. Neurologix release

> The RNAi company Silence Therapeutics has named Thomas Christély as CEO. Release

> Steven Burrill's long delayed Elk Run biotech park in Minnesota may be close to signing its first, small, biotech tenant. Report

> Spectrum Pharmaceuticals says it has garnered about $25 million in proceeds from the exercise of long-term warrants issued in 2005. Release

Pharma News

@FiercePharma: FTC's nosing around Valeant's deals to buy Dermik and Ortho Dermatologics, but $VRX still expects to close this year. Release | Follow @FiercePharma

> Pharma pledges help on patient access to chronic-disease meds. Report

> Which drug will dominate growing prostate-cancer market? Story

> Amphastar's Lovenox copy likely to shake market. News

> Pfizer to plow $200M into Irish biotech plant. Item

> Obama plan hits pharma with rebates, pay-to-delay ban. Report

Biotech Research News

> UM cuts the ribbon on new biomed research site. Report 

> NIH supports "super" antioxidant program to shield against sun risks. News 

> JDRF presents a $100,000 challenge for breakthrough ideas on diabetes. Article 

> Green dye lights up hidden ovarian tumor targets for cancer surgeons. Item

Manufacturing News

> Offshore generics makers eye biosimilars. Report 

> Pharma discharge study reveals big impact on fish. News 

> Flying high on Elan deal, Alkermes gets to work on Big Pharma project. Story 

> Genzyme's shortage opens door to rival Protalix. Article 

> SCM flexes formulation muscle for Mitovie. News 

> Sun gets NJ plant back on GMP track, still working on Detroit facility. Piece

And Finally... Reports of new outbreaks of bird flu in Asia have once again stirred concerns of a possible pandemic. Flu expert Robert Webster says that this is one threat that should not be ignored. "Nature has already shown us that there is a virus out there that kills 50% of the people it infects. We ignore it at our peril." Story

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.